Original Research

Published on 03 Mar 2023

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

in Drugs Outcomes Research and Policies

Maciej Niewada
Tomasz Macioch
Magdalena Konarska
Aneta Mela
Adam Goszczyński
Bogusława Przekopińska
Karolina Rajkiewicz
Piotr Wysocki
Maciej Krzakowski

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1063178

5,578 views
4 citations

Original Research

Published on 02 Mar 2023

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis

in Drugs Outcomes Research and Policies

Tianyang Hu
Yiting Liu
Yake Lou

Frontiers in Pharmacology

doi 10.3389/fphar.2023.925375

2,324 views

Perspective

Published on 02 Mar 2023

China’s drug clinical trial institution record-keeping system: Qualification requirements for PI are the key

in Drugs Outcomes Research and Policies

Nanqu Huang
Wendi Huang
Yong Luo
Juan Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1052977

2,170 views
1 citation

Original Research

Published on 02 Mar 2023

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China

in Drugs Outcomes Research and Policies

Shixian Liu
Lei Dou
Shunping Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1055727

4,010 views
11 citations

Original Research

Published on 02 Mar 2023

A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019

in Drugs Outcomes Research and Policies

Mingyuan Cai
Liang Zhou
Daihui Gao
Dan Mei
Bo Zhang
Wei Zuo
Qing Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1022134

2,507 views
3 citations

Editorial

Published on 02 Mar 2023

Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022

in Drugs Outcomes Research and Policies

Rachel M. A. Linger
Joseph O. Fadare
Ye Shen
Lon J. Van Winkle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1162703

948 views

Policy and Practice Reviews

Published on 28 Feb 2023

Access to medicines for rare diseases: A European regulatory roadmap for academia

in Drugs Outcomes Research and Policies

Noa Rosenberg
Sibren van den Berg
Nina N. Stolwijk
Bart A. W. Jacobs
Hendrika C. Post
Anna M. G. Pasmooij
Saco J. de Visser
Carla E. M. Hollak

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1142351

8,071 views
3 citations

Original Research

Published on 24 Feb 2023

Quality of life associated with immunosuppressant treatment adherence in liver transplant recipients: A cross-sectional study

in Drugs Outcomes Research and Policies

Mojtaba Shafiekhani
Farbod Shahabinezhad
Zahra Tavakoli
Tahereh Tarakmeh
Elham Haem
Negar Sari
Shohreh Nasirabadi
Masoud Dehghani

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1051350

2,260 views
4 citations

Brief Research Report

Published on 22 Feb 2023

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine

in Drugs Outcomes Research and Policies

Chao Zhang
Yudan Ding
Zhenzhen Wu
Juan Wang
Xiangping Wu
Weiwei Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1097600

1,989 views
2 citations

Systematic Review

Published on 20 Feb 2023

The effects and safety of anticoagulation or antiplatelet therapy following TIPS in cirrhotic patients with portal hypertension: A meta-analysis

in Drugs Outcomes Research and Policies

Xiaotong Xu
Yunlai Fu
Minjie Jiang
Muchen Wu
Jing Wu
Qinghua Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1116177

3,671 views
1 citation

Systematic Review

Published on 16 Feb 2023

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis

in Drugs Outcomes Research and Policies

Rui Hu
Tao Yuan
Hui Wang
Jianglin Zhao
Liya Shi
Quankai Li
Chunmei Zhu
Na Su
Shengzhao Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1089272

3,272 views
6 citations

Original Research

Published on 15 Feb 2023

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China

in Drugs Outcomes Research and Policies

Xiaotong Wen
Yue Wang
Xiaoze Chen
Yuxin Liu
Zongfu Mao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1088723

1,376 views
1 citation

Original Research

Published on 14 Feb 2023

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis

in Drugs Outcomes Research and Policies

Gengwei Huo
Wenjie Liu
Shuo Kang
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1131219

2,388 views
1 citation

Editorial

Published on 14 Feb 2023

Editorial: Pharmaceutical policy, impact and health outcomes

in Drugs Outcomes Research and Policies

Hye-Young Kwon
Brian Godman

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1150055

2,035 views
2 citations

Systematic Review

Published on 10 Feb 2023

Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Lina Naseralallah
Malkan Khatib
Azhar Al-Khulaifi
Mohammed Danjuma

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1122898

4,041 views
7 citations

Original Research

Published on 08 Feb 2023

Regional variations in excessive polypharmacy and potentially inappropriate drug use among older adults in Sweden: Trends from 2006 to 2020

in Drugs Outcomes Research and Policies

Jonas W. Wastesson
Johan Fritzell
Bo Burström
Kristina Johnell
Johan Fastbom

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1030849

1,919 views
3 citations

Navigation group

Articles

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis

China’s drug clinical trial institution record-keeping system: Qualification requirements for PI are the key

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China

A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019

Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022

Access to medicines for rare diseases: A European regulatory roadmap for academia

Quality of life associated with immunosuppressant treatment adherence in liver transplant recipients: A cross-sectional study

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine

The effects and safety of anticoagulation or antiplatelet therapy following TIPS in cirrhotic patients with portal hypertension: A meta-analysis

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis

Editorial: Pharmaceutical policy, impact and health outcomes

Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta-analysis

Regional variations in excessive polypharmacy and potentially inappropriate drug use among older adults in Sweden: Trends from 2006 to 2020